Novartis blames site closure on pricing pressure in US generics market

Novartis’ (NOVN: VX) closure of a manufacturing unit in Broomfield, Colorado, is due to wider pressures affecting sales of its generics in the USA, the Swiss pharma giant has said.

Around 450 jobs at the site will be affected by the closure of commercial production operations there and although Novartis will consolidate the production of drug ingredients at a plant in Wilson, North Carolina, its generics unit Sandoz is reducing or ceasing production of some generics.

"With several products no longer competitive in saturated markets, we have made the decision to discontinue or divest these"